Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-15-008392
Filing Date
2015-11-06
Accepted
2015-11-06 08:26:58
Documents
10
Period of Report
2015-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q mrtx-20150930x10q.htm 10-Q 793528
2 EXHIBIT 31.1 mrtx93015ex311.htm EX-31.1 12045
3 EXHIBIT 31.2 mrtx93015ex312.htm EX-31.2 12945
4 EXHIBIT 32.1 mrtx93015ex321.htm EX-32.1 7889
  Complete submission text file 0001628280-15-008392.txt   3459512

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT mrtx-20150930.xml EX-101.INS 722328
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20150930.xsd EX-101.SCH 23537
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20150930_cal.xml EX-101.CAL 50989
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20150930_def.xml EX-101.DEF 61547
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20150930_lab.xml EX-101.LAB 290799
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20150930_pre.xml EX-101.PRE 160764
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

EIN.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35921 | Film No.: 151202526
SIC: 2834 Pharmaceutical Preparations